Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

May 31, 2018 updated by: Boehringer Ingelheim

A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]

The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD.

Study Overview

Status

Completed

Conditions

Pulmonary Disease, Chronic Obstructive

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

7903

Phase

Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Argentina
- - Bahía Blanca, Argentina
    - 1237.19.54015 Boehringer Ingelheim Investigational Site
  - Berazategui, Argentina
    - 1237.19.54014 Boehringer Ingelheim Investigational Site
  - Capital Federal, Argentina
    - 1237.19.54003 Boehringer Ingelheim Investigational Site
  - Capital Federal, Argentina
    - 1237.19.54004 Boehringer Ingelheim Investigational Site
  - Capital Federal, Argentina
    - 1237.19.54007 Boehringer Ingelheim Investigational Site
  - Ciudad de Buenos Aires, Argentina
    - 1237.19.54011 Boehringer Ingelheim Investigational Site
  - Ciudad de Buenos Aires, Argentina
    - 1237.19.54018 Boehringer Ingelheim Investigational Site
  - La Plata, Argentina
    - 1237.19.54010 Boehringer Ingelheim Investigational Site
  - Mar del Plata, Argentina
    - 1237.19.54012 Boehringer Ingelheim Investigational Site
  - Mar del Plata, Argentina
    - 1237.19.54017 Boehringer Ingelheim Investigational Site
  - Mar del Plata, Argentina
    - 1237.19.54019 Boehringer Ingelheim Investigational Site
  - Mendoza, Argentina
    - 1237.19.54005 Boehringer Ingelheim Investigational Site
  - Quilmes, Argentina
    - 1237.19.54006 Boehringer Ingelheim Investigational Site
  - Rosario, Argentina
    - 1237.19.54013 Boehringer Ingelheim Investigational Site
  - San Isidro, Argentina
    - 1237.19.54016 Boehringer Ingelheim Investigational Site
  - San Miguel de Tucuman, Argentina
    - 1237.19.54002 Boehringer Ingelheim Investigational Site
  - Tucumán, Argentina
    - 1237.19.54001 Boehringer Ingelheim Investigational Site
Australia
- New South Wales
  - Campbelltown, New South Wales, Australia
    - 1237.19.61012 Boehringer Ingelheim Investigational Site
  - Kogarah, New South Wales, Australia
    - 1237.19.61011 Boehringer Ingelheim Investigational Site
  - Randwick, New South Wales, Australia
    - 1237.19.61008 Boehringer Ingelheim Investigational Site
- Queensland
  - Cairns, Queensland, Australia
    - 1237.19.61010 Boehringer Ingelheim Investigational Site
  - Chermside, Queensland, Australia
    - 1237.19.61006 Boehringer Ingelheim Investigational Site
- South Australia
  - Daw Park, South Australia, Australia
    - 1237.19.61001 Boehringer Ingelheim Investigational Site
  - Kent Town, South Australia, Australia
    - 1237.19.61002 Boehringer Ingelheim Investigational Site
  - Woodville, South Australia, Australia
    - 1237.19.61007 Boehringer Ingelheim Investigational Site
- Victoria
  - Box Hill, Victoria, Australia
    - 1237.19.61013 Boehringer Ingelheim Investigational Site
  - Melbourne, Victoria, Australia
    - 1237.19.61003 Boehringer Ingelheim Investigational Site
  - Parkville, Victoria, Australia
    - 1237.19.61009 Boehringer Ingelheim Investigational Site
- Western Australia
  - Murdoch, Western Australia, Australia
    - 1237.19.61004 Boehringer Ingelheim Investigational Site
Austria
- - Feldbach, Austria
    - 1237.19.43006 Boehringer Ingelheim Investigational Site
  - Graz, Austria
    - 1237.19.43004 Boehringer Ingelheim Investigational Site
  - Leoben, Austria
    - 1237.19.43003 Boehringer Ingelheim Investigational Site
  - Linz, Austria
    - 1237.19.43001 Boehringer Ingelheim Investigational Site
  - Ryazan, Austria
    - 1237.19.70001 Boehringer Ingelheim Investigational Site
  - Salzburg, Austria
    - 1237.19.43005 Boehringer Ingelheim Investigational Site
  - Wien, Austria
    - 1237.19.43002 Boehringer Ingelheim Investigational Site
Belgium
- - Brussel, Belgium
    - 1237.19.32001 Boehringer Ingelheim Investigational Site
  - Brussels, Belgium
    - 1237.19.32007 Boehringer Ingelheim Investigational Site
  - Gilly, Belgium
    - 1237.19.32006 Boehringer Ingelheim Investigational Site
  - Jambes, Belgium
    - 1237.19.32004 Boehringer Ingelheim Investigational Site
  - Lebbeke, Belgium
    - 1237.19.32003 Boehringer Ingelheim Investigational Site
  - Turnhout, Belgium
    - 1237.19.32002 Boehringer Ingelheim Investigational Site
  - Zichem, Belgium
    - 1237.19.32005 Boehringer Ingelheim Investigational Site
Brazil
- - Belo Horizonte, Brazil
    - 1237.19.55007 Boehringer Ingelheim Investigational Site
  - Botucatu, Brazil
    - 1237.19.55013 Boehringer Ingelheim Investigational Site
  - Goiania, Brazil
    - 1237.19.55011 Boehringer Ingelheim Investigational Site
  - Porto Alegre, Brazil
    - 1237.19.55002 Boehringer Ingelheim Investigational Site
  - Porto Alegre, Brazil
    - 1237.19.55006 Boehringer Ingelheim Investigational Site
  - Porto Alegre, Brazil
    - 1237.19.55010 Boehringer Ingelheim Investigational Site
  - Porto Alegre, Brazil
    - 1237.19.55012 Boehringer Ingelheim Investigational Site
  - Santo Andre, Brazil
    - 1237.19.55014 Boehringer Ingelheim Investigational Site
  - Sao Paulo, Brazil
    - 1237.19.55005 Boehringer Ingelheim Investigational Site
  - Sao Paulo, Brazil
    - 1237.19.55008 Boehringer Ingelheim Investigational Site
  - São Paulo, Brazil
    - 1237.19.55001 Boehringer Ingelheim Investigational Site
  - Vitoria, Brazil
    - 1237.19.55009 Boehringer Ingelheim Investigational Site
Bulgaria
- - Plovdiv, Bulgaria
    - 1237.19.35905 Boehringer Ingelheim Investigational Site
  - Ruse, Bulgaria
    - 1237.19.35902 Boehringer Ingelheim Investigational Site
  - Sofia, Bulgaria
    - 1237.19.35903 Boehringer Ingelheim Investigational Site
  - Sofia, Bulgaria
    - 1237.19.35904 Boehringer Ingelheim Investigational Site
  - Sofia, Bulgaria
    - 1237.19.35906 Boehringer Ingelheim Investigational Site
  - Troyan, Bulgaria
    - 1237.19.35907 Boehringer Ingelheim Investigational Site
  - Varna, Bulgaria
    - 1237.19.35901 Boehringer Ingelheim Investigational Site
  - Vidin, Bulgaria
    - 1237.19.35908 Boehringer Ingelheim Investigational Site
Canada
- - Quebec, Canada
    - 1237.19.20014 Boehringer Ingelheim Investigational Site
- Alberta
  - Calgary, Alberta, Canada
    - 1237.19.20011 Boehringer Ingelheim Investigational Site
  - Calgary, Alberta, Canada
    - 1237.19.20020 Boehringer Ingelheim Investigational Site
  - Edmonton, Alberta, Canada
    - 1237.19.20016 Boehringer Ingelheim Investigational Site
  - Edmonton, Alberta, Canada
    - 1237.19.20025 Boehringer Ingelheim Investigational Site
- British Columbia
  - Coquitlam, British Columbia, Canada
    - 1237.19.20035 Boehringer Ingelheim Investigational Site
  - Kelowna, British Columbia, Canada
    - 1237.19.20034 Boehringer Ingelheim Investigational Site
  - Maple Ridge, British Columbia, Canada
    - 1237.19.20041 Boehringer Ingelheim Investigational Site
  - Vancouver, British Columbia, Canada
    - 1237.19.20010 Boehringer Ingelheim Investigational Site
  - Vancouver, British Columbia, Canada
    - 1237.19.20033 Boehringer Ingelheim Investigational Site
  - Vancouver, British Columbia, Canada
    - 1237.19.20036 Boehringer Ingelheim Investigational Site
- Manitoba
  - Winnipeg, Manitoba, Canada
    - 1237.19.20015 Boehringer Ingelheim Investigational Site
- New Brunswick
  - Moncton, New Brunswick, Canada
    - 1237.19.20021 Boehringer Ingelheim Investigational Site
  - Saint John, New Brunswick, Canada
    - 1237.19.20006 Boehringer Ingelheim Investigational Site
- Newfoundland and Labrador
  - Saint John¿s, Newfoundland and Labrador, Canada
    - 1237.19.20013 Boehringer Ingelheim Investigational Site
- Ontario
  - Burlington, Ontario, Canada
    - 1237.19.20018 Boehringer Ingelheim Investigational Site
  - Corunna, Ontario, Canada
    - 1237.19.20029 Boehringer Ingelheim Investigational Site
  - Courtice, Ontario, Canada
    - 1237.19.20009 Boehringer Ingelheim Investigational Site
  - Grimsby, Ontario, Canada
    - 1237.19.20019 Boehringer Ingelheim Investigational Site
  - Hamilton, Ontario, Canada
    - 1237.19.20017 Boehringer Ingelheim Investigational Site
  - Hamilton, Ontario, Canada
    - 1237.19.20026 Boehringer Ingelheim Investigational Site
  - Hamilton, Ontario, Canada
    - 1237.19.20038 Boehringer Ingelheim Investigational Site
  - London, Ontario, Canada
    - 1237.19.20022 Boehringer Ingelheim Investigational Site
  - Ottawa, Ontario, Canada
    - 1237.19.20040 Boehringer Ingelheim Investigational Site
  - Sarnia, Ontario, Canada
    - 1237.19.20030 Boehringer Ingelheim Investigational Site
  - Toronto, Ontario, Canada
    - 1237.19.20005 Boehringer Ingelheim Investigational Site
  - Toronto, Ontario, Canada
    - 1237.19.20037 Boehringer Ingelheim Investigational Site
  - Waterloo, Ontario, Canada
    - 1237.19.20012 Boehringer Ingelheim Investigational Site
  - Windsor, Ontario, Canada
    - 1237.19.20007 Boehringer Ingelheim Investigational Site
- Quebec
  - Longueuil, Quebec, Canada
    - 1237.19.20004 Boehringer Ingelheim Investigational Site
  - Montreal, Quebec, Canada
    - 1237.19.20032 Boehringer Ingelheim Investigational Site
  - Point Claire, Quebec, Canada
    - 1237.19.20008 Boehringer Ingelheim Investigational Site
  - St-Charles-Borromée, Quebec, Canada
    - 1237.19.20031 Boehringer Ingelheim Investigational Site
  - Ste-Foy, Quebec, Canada
    - 1237.19.20023 Boehringer Ingelheim Investigational Site
  - Trois-Rivieres, Quebec, Canada
    - 1237.19.20039 Boehringer Ingelheim Investigational Site
  - Victoriaville, Quebec, Canada
    - 1237.19.20003 Boehringer Ingelheim Investigational Site
- Saskatchewan
  - Saskatoon, Saskatchewan, Canada
    - 1237.19.20002 Boehringer Ingelheim Investigational Site
  - Saskatoon, Saskatchewan, Canada
    - 1237.19.20027 Boehringer Ingelheim Investigational Site
Chile
- - Quillota, Chile
    - 1237.19.53004 Boehringer Ingelheim Investigational Site
  - San Miguel, Chile
    - 1237.19.53003 Boehringer Ingelheim Investigational Site
  - Santiago de Chile, Chile
    - 1237.19.53002 Boehringer Ingelheim Investigational Site
Colombia
- - Bogotá, Colombia
    - 1237.19.57002 Boehringer Ingelheim Investigational Site
  - Bogotá, Colombia
    - 1237.19.57004 Boehringer Ingelheim Investigational Site
  - Bogotá, Colombia
    - 1237.19.57005 Boehringer Ingelheim Investigational Site
  - Cali, Colombia
    - 1237.19.57003 Boehringer Ingelheim Investigational Site
  - Medellín, Colombia
    - 1237.19.57006 Boehringer Ingelheim Investigational Site
Croatia
- - Rijeka, Croatia
    - 1237.19.38501 Boehringer Ingelheim Investigational Site
  - Zagreb, Croatia
    - 1237.19.38502 Boehringer Ingelheim Investigational Site
  - Zagreb, Croatia
    - 1237.19.38503 Boehringer Ingelheim Investigational Site
Czechia
- - Beroun, Czechia
    - 1237.19.42001 Boehringer Ingelheim Investigational Site
  - Cesky Krumlov, Czechia
    - 1237.19.42010 Boehringer Ingelheim Investigational Site
  - Hradec Kralove, Czechia
    - 1237.19.42004 Boehringer Ingelheim Investigational Site
  - Jindrichuv Hradec, Czechia
    - 1237.19.42002 Boehringer Ingelheim Investigational Site
  - Krnov, Czechia
    - 1237.19.42006 Boehringer Ingelheim Investigational Site
  - Liberec, Czechia
    - 1237.19.42007 Boehringer Ingelheim Investigational Site
  - Melnik, Czechia
    - 1237.19.42003 Boehringer Ingelheim Investigational Site
  - Prague 8, Czechia
    - 1237.19.42005 Boehringer Ingelheim Investigational Site
  - Praha, Czechia
    - 1237.19.42008 Boehringer Ingelheim Investigational Site
  - Varnsdorf, Czechia
    - 1237.19.42009 Boehringer Ingelheim Investigational Site
Denmark
- - Aarhus, Denmark
    - 1237.19.45007 Boehringer Ingelheim Investigational Site
  - Holstebro, Denmark
    - 1237.19.45006 Boehringer Ingelheim Investigational Site
  - Hvidovre, Denmark
    - 1237.19.45002 Boehringer Ingelheim Investigational Site
  - Kolding, Denmark
    - 1237.19.45005 Boehringer Ingelheim Investigational Site
  - Odense, Denmark
    - 1237.19.45001 Boehringer Ingelheim Investigational Site
  - Roskilde, Denmark
    - 1237.19.45008 Boehringer Ingelheim Investigational Site
  - Vaerløse, Denmark
    - 1237.19.45003 Boehringer Ingelheim Investigational Site
  - Ålborg, Denmark
    - 1237.19.45004 Boehringer Ingelheim Investigational Site
Finland
- - Helsinki, Finland
    - 1237.19.35804 Boehringer Ingelheim Investigational Site
  - Oulu, Finland
    - 1237.19.35805 Boehringer Ingelheim Investigational Site
  - Turku, Finland
    - 1237.19.35801 Boehringer Ingelheim Investigational Site
  - Turku, Finland
    - 1237.19.35803 Boehringer Ingelheim Investigational Site
France
- - Cannes, France
    - 1237.19.33016 Boehringer Ingelheim Investigational Site
  - La Tronche, France
    - 1237.19.33014 Boehringer Ingelheim Investigational Site
  - MARSEILLE Cedex 08, France
    - 1237.19.33020 Boehringer Ingelheim Investigational Site
  - Marseille, France
    - 1237.19.33013 Boehringer Ingelheim Investigational Site
  - Montpellier cedex 5, France
    - 1237.19.33003 Boehringer Ingelheim Investigational Site
  - Nantes Cedex 01, France
    - 1237.19.33024 Boehringer Ingelheim Investigational Site
  - Nice, France
    - 1237.19.33017 Boehringer Ingelheim Investigational Site
  - Nîmes, France
    - 1237.19.33019 Boehringer Ingelheim Investigational Site
  - Nîmes cedex 9, France
    - 1237.19.33018 Boehringer Ingelheim Investigational Site
  - Paris, France
    - 1237.19.33001 Boehringer Ingelheim Investigational Site
  - Pessac, France
    - 1237.19.33002 Boehringer Ingelheim Investigational Site
  - Reims, France
    - 1237.19.33006 Boehringer Ingelheim Investigational Site
  - Rennes Cedex 9, France
    - 1237.19.33021 Boehringer Ingelheim Investigational Site
  - Saint Laurent du Var, France
    - 1237.19.33005 Boehringer Ingelheim Investigational Site
  - Saint Pierre - La Réunion, France
    - 1237.19.33012 Boehringer Ingelheim Investigational Site
  - Strasbourg, France
    - 1237.19.33022 Boehringer Ingelheim Investigational Site
  - TOURS Cedex 9, France
    - 1237.19.33023 Boehringer Ingelheim Investigational Site
  - Toulouse cedex 9, France
    - 1237.19.33007 Boehringer Ingelheim Investigational Site
  - Vieux Condé, France
    - 1237.19.33010 Boehringer Ingelheim Investigational Site
Germany
- - Ahlen, Germany
    - 1237.19.49041 Boehringer Ingelheim Investigational Site
  - Aschaffenburg, Germany
    - 1237.19.49004 Boehringer Ingelheim Investigational Site
  - Augsburg, Germany
    - 1237.19.49059 Boehringer Ingelheim Investigational Site
  - Bad Wörishofen, Germany
    - 1237.19.49042 Boehringer Ingelheim Investigational Site
  - Bamberg, Germany
    - 1237.19.49072 Boehringer Ingelheim Investigational Site
  - Bergisch Gladbach, Germany
    - 1237.19.49024 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49009 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49011 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49018 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49025 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49026 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49029 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49035 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49043 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49058 Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - 1237.19.49065 Boehringer Ingelheim Investigational Site
  - Bielefeld, Germany
    - 1237.19.49076 Boehringer Ingelheim Investigational Site
  - Bochum, Germany
    - 1237.19.49064 Boehringer Ingelheim Investigational Site
  - Bonn, Germany
    - 1237.19.49048 Boehringer Ingelheim Investigational Site
  - Düren, Germany
    - 1237.19.49002 Boehringer Ingelheim Investigational Site
  - Essen, Germany
    - 1237.19.49012 Boehringer Ingelheim Investigational Site
  - Frankfurt, Germany
    - 1237.19.49017 Boehringer Ingelheim Investigational Site
  - Frankfurt, Germany
    - 1237.19.49019 Boehringer Ingelheim Investigational Site
  - Frankfurt, Germany
    - 1237.19.49052 Boehringer Ingelheim Investigational Site
  - Frankfurt, Germany
    - 1237.19.49062 Boehringer Ingelheim Investigational Site
  - Fulda, Germany
    - 1237.19.49044 Boehringer Ingelheim Investigational Site
  - Fürstenwalde, Germany
    - 1237.19.49057 Boehringer Ingelheim Investigational Site
  - Großhansdorf, Germany
    - 1237.19.49001 Boehringer Ingelheim Investigational Site
  - Gütersloh, Germany
    - 1237.19.49008 Boehringer Ingelheim Investigational Site
  - Halle/Saale, Germany
    - 1237.19.49028 Boehringer Ingelheim Investigational Site
  - Hamburg, Germany
    - 1237.19.49038 Boehringer Ingelheim Investigational Site
  - Hannover, Germany
    - 1237.19.49055 Boehringer Ingelheim Investigational Site
  - Hannover, Germany
    - 1237.19.49077 Boehringer Ingelheim Investigational Site
  - Heidelberg, Germany
    - 1237.19.49022 Boehringer Ingelheim Investigational Site
  - Höchstädt, Germany
    - 1237.19.49056 Boehringer Ingelheim Investigational Site
  - Kiel, Germany
    - 1237.19.49049 Boehringer Ingelheim Investigational Site
  - Koblenz, Germany
    - 1237.19.49005 Boehringer Ingelheim Investigational Site
  - Köln, Germany
    - 1237.19.49034 Boehringer Ingelheim Investigational Site
  - Landsberg am Lech, Germany
    - 1237.19.49073 Boehringer Ingelheim Investigational Site
  - Leipzig, Germany
    - 1237.19.49003 Boehringer Ingelheim Investigational Site
  - Leipzig, Germany
    - 1237.19.49007 Boehringer Ingelheim Investigational Site
  - Leipzig, Germany
    - 1237.19.49030 Boehringer Ingelheim Investigational Site
  - Leipzig, Germany
    - 1237.19.49061 Boehringer Ingelheim Investigational Site
  - Leipzig, Germany
    - 1237.19.49063 Boehringer Ingelheim Investigational Site
  - Leipzig, Germany
    - 1237.19.49070 Boehringer Ingelheim Investigational Site
  - Leverkusen, Germany
    - 1237.19.49010 Boehringer Ingelheim Investigational Site
  - Lübeck, Germany
    - 1237.19.49037 Boehringer Ingelheim Investigational Site
  - Mannheim, Germany
    - 1237.19.49016 Boehringer Ingelheim Investigational Site
  - Mannheim, Germany
    - 1237.19.49046 Boehringer Ingelheim Investigational Site
  - Marburg, Germany
    - 1237.19.49036 Boehringer Ingelheim Investigational Site
  - Minden, Germany
    - 1237.19.49054 Boehringer Ingelheim Investigational Site
  - München, Germany
    - 1237.19.49006 Boehringer Ingelheim Investigational Site
  - München, Germany
    - 1237.19.49013 Boehringer Ingelheim Investigational Site
  - Paderborn, Germany
    - 1237.19.49047 Boehringer Ingelheim Investigational Site
  - Peine, Germany
    - 1237.19.49014 Boehringer Ingelheim Investigational Site
  - Potsdam, Germany
    - 1237.19.49074 Boehringer Ingelheim Investigational Site
  - Radebeul, Germany
    - 1237.19.49045 Boehringer Ingelheim Investigational Site
  - Rheine, Germany
    - 1237.19.49053 Boehringer Ingelheim Investigational Site
  - Rüdersdorf, Germany
    - 1237.19.49060 Boehringer Ingelheim Investigational Site
  - Solingen, Germany
    - 1237.19.49050 Boehringer Ingelheim Investigational Site
  - Teuchern, Germany
    - 1237.19.49032 Boehringer Ingelheim Investigational Site
  - Wardenburg, Germany
    - 1237.19.49051 Boehringer Ingelheim Investigational Site
  - Wiesloch, Germany
    - 1237.19.49040 Boehringer Ingelheim Investigational Site
  - Witten, Germany
    - 1237.19.49023 Boehringer Ingelheim Investigational Site
Greece
- - Athens, Greece
    - 1237.19.30003 Boehringer Ingelheim Investigational Site
  - Athens, Greece
    - 1237.19.30007 Boehringer Ingelheim Investigational Site
  - Athens, Greece
    - 1237.19.30008 Boehringer Ingelheim Investigational Site
  - Heraklion, Greece
    - 1237.19.30004 Boehringer Ingelheim Investigational Site
  - Nafplio, Greece
    - 1237.19.30002 Boehringer Ingelheim Investigational Site
  - Serres, Greece
    - 1237.19.30005 Boehringer Ingelheim Investigational Site
  - Thessaloniki, Greece
    - 1237.19.30001 Boehringer Ingelheim Investigational Site
  - Thessaloniki, Greece
    - 1237.19.30006 Boehringer Ingelheim Investigational Site
Guatemala
- - Guatemala, Guatemala
    - 1237.19.50201 Boehringer Ingelheim Investigational Site
  - Guatemala, Guatemala
    - 1237.19.50202 Boehringer Ingelheim Investigational Site
  - Guatemala, Guatemala
    - 1237.19.50203 Boehringer Ingelheim Investigational Site
  - Guatemala, Guatemala
    - 1237.19.50204 Boehringer Ingelheim Investigational Site
  - Guatemala, Guatemala
    - 1237.19.50205 Boehringer Ingelheim Investigational Site
Hong Kong
- - Hong Kong, Hong Kong
    - 1237.19.85201 Boehringer Ingelheim Investigational Site
  - Hong Kong, Hong Kong
    - 1237.19.85202 Boehringer Ingelheim Investigational Site
  - Hong Kong, Hong Kong
    - 1237.19.85203 Boehringer Ingelheim Investigational Site
Hungary
- - Budapest, Hungary
    - 1237.19.36006 Boehringer Ingelheim Investigational Site
  - Budapest, Hungary
    - 1237.19.36012 Boehringer Ingelheim Investigational Site
  - Debrecen, Hungary
    - 1237.19.36005 Boehringer Ingelheim Investigational Site
  - Debrecen, Hungary
    - 1237.19.36015 Boehringer Ingelheim Investigational Site
  - Edeleny, Hungary
    - 1237.19.36008 Boehringer Ingelheim Investigational Site
  - Farkasgyepu, Hungary
    - 1237.19.36011 Boehringer Ingelheim Investigational Site
  - Godollo, Hungary
    - 1237.19.36002 Boehringer Ingelheim Investigational Site
  - Hajdunanas, Hungary
    - 1237.19.36014 Boehringer Ingelheim Investigational Site
  - Kapuvar, Hungary
    - 1237.19.36013 Boehringer Ingelheim Investigational Site
  - Komarom, Hungary
    - 1237.19.36009 Boehringer Ingelheim Investigational Site
  - Nyiregyhaza, Hungary
    - 1237.19.36007 Boehringer Ingelheim Investigational Site
  - Pecs, Hungary
    - 1237.19.36003 Boehringer Ingelheim Investigational Site
  - Pecs, Hungary
    - 1237.19.36004 Boehringer Ingelheim Investigational Site
  - Szazhalombatta, Hungary
    - 1237.19.36010 Boehringer Ingelheim Investigational Site
  - Szeged, Hungary
    - 1237.19.36001 Boehringer Ingelheim Investigational Site
India
- - Ahmadabad, India
    - 1237.19.91016 Boehringer Ingelheim Investigational Site
  - Ahmedabad, India
    - 1237.19.91013 Boehringer Ingelheim Investigational Site
  - Ahmedabad, India
    - 1237.19.91040 Boehringer Ingelheim Investigational Site
  - Bangalore, India
    - 1237.19.91032 Boehringer Ingelheim Investigational Site
  - Coimbatore, India
    - 1237.19.91004 Boehringer Ingelheim Investigational Site
  - Gurgaon, India
    - 1237.19.91033 Boehringer Ingelheim Investigational Site
  - Hyderabad, India
    - 1237.19.91005 Boehringer Ingelheim Investigational Site
  - Hyderabad, India
    - 1237.19.91019 Boehringer Ingelheim Investigational Site
  - Hyderabad, India
    - 1237.19.91020 Boehringer Ingelheim Investigational Site
  - Hyderabad, India
    - 1237.19.91025 Boehringer Ingelheim Investigational Site
  - Jaipur, India
    - 1237.19.91006 Boehringer Ingelheim Investigational Site
  - Jaipur, India
    - 1237.19.91042 Boehringer Ingelheim Investigational Site
  - Jaipur, India
    - 1237.19.91044 Boehringer Ingelheim Investigational Site
  - Karamsad, India
    - 1237.19.91026 Boehringer Ingelheim Investigational Site
  - Kolkata, India
    - 1237.19.91034 Boehringer Ingelheim Investigational Site
  - Ludhiana, India
    - 1237.19.91010 Boehringer Ingelheim Investigational Site
  - Madurai, India
    - 1237.19.91007 Boehringer Ingelheim Investigational Site
  - Mysore, India
    - 1237.19.91014 Boehringer Ingelheim Investigational Site
  - Mysore, India
    - 1237.19.91021 Boehringer Ingelheim Investigational Site
  - Nagpur, India
    - 1237.19.91001 Boehringer Ingelheim Investigational Site
  - Nagpur, India
    - 1237.19.91002 Boehringer Ingelheim Investigational Site
  - Nagpur, India
    - 1237.19.91003 Boehringer Ingelheim Investigational Site
  - New Delhi, India
    - 1237.19.91027 Boehringer Ingelheim Investigational Site
  - Panjim, India
    - 1237.19.91024 Boehringer Ingelheim Investigational Site
  - Pune, India
    - 1237.19.91023 Boehringer Ingelheim Investigational Site
  - Pune, India
    - 1237.19.91035 Boehringer Ingelheim Investigational Site
  - Vellore, India
    - 1237.19.91008 Boehringer Ingelheim Investigational Site
  - Vishakhapatnam, India
    - 1237.19.91028 Boehringer Ingelheim Investigational Site
Ireland
- - Dublin 24, Ireland
    - 1237.19.35301 Boehringer Ingelheim Investigational Site
  - Wilton, Ireland
    - 1237.19.35302 Boehringer Ingelheim Investigational Site
Italy
- - Cittadella (PD), Italy
    - 1237.19.39011 Boehringer Ingelheim Investigational Site
  - Ferrara, Italy
    - 1237.19.39014 Boehringer Ingelheim Investigational Site
  - Messina, Italy
    - 1237.19.39010 Boehringer Ingelheim Investigational Site
  - Milano, Italy
    - 1237.19.39002 Boehringer Ingelheim Investigational Site
  - Milano, Italy
    - 1237.19.39016 Boehringer Ingelheim Investigational Site
  - Milano, Italy
    - 1237.19.39023 Boehringer Ingelheim Investigational Site
  - Monza, Italy
    - 1237.19.39015 Boehringer Ingelheim Investigational Site
  - Padova, Italy
    - 1237.19.39025 Boehringer Ingelheim Investigational Site
  - Palermo, Italy
    - 1237.19.39024 Boehringer Ingelheim Investigational Site
  - Parma, Italy
    - 1237.19.39006 Boehringer Ingelheim Investigational Site
  - Pavia, Italy
    - 1237.19.39005 Boehringer Ingelheim Investigational Site
  - Perugia, Italy
    - 1237.19.39007 Boehringer Ingelheim Investigational Site
  - Piacenza, Italy
    - 1237.19.39008 Boehringer Ingelheim Investigational Site
  - Pisa, Italy
    - 1237.19.39001 Boehringer Ingelheim Investigational Site
  - Pisa, Italy
    - 1237.19.39020 Boehringer Ingelheim Investigational Site
  - Pordenone, Italy
    - 1237.19.39013 Boehringer Ingelheim Investigational Site
  - Roma, Italy
    - 1237.19.39003 Boehringer Ingelheim Investigational Site
  - Roma, Italy
    - 1237.19.39004 Boehringer Ingelheim Investigational Site
  - Roma, Italy
    - 1237.19.39012 Boehringer Ingelheim Investigational Site
  - San Pietro Vernotico (BR), Italy
    - 1237.19.39021 Boehringer Ingelheim Investigational Site
  - Sassari, Italy
    - 1237.19.39017 Boehringer Ingelheim Investigational Site
  - Scafati (SA), Italy
    - 1237.19.39019 Boehringer Ingelheim Investigational Site
Japan
- - Aichi, Komaki, Japan
    - 1237.19.81072 Boehringer Ingelheim Investigational Site
  - Aichi, Nagoya, Japan
    - 1237.19.81070 Boehringer Ingelheim Investigational Site
  - Aichi, Nagoya, Japan
    - 1237.19.81073 Boehringer Ingelheim Investigational Site
  - Aichi, Nagoya, Japan
    - 1237.19.81074 Boehringer Ingelheim Investigational Site
  - Aichi, Obu, Japan
    - 1237.19.81071 Boehringer Ingelheim Investigational Site
  - Aichi, Seto, Japan
    - 1237.19.81069 Boehringer Ingelheim Investigational Site
  - Chiba, Chiba, Japan
    - 1237.19.81030 Boehringer Ingelheim Investigational Site
  - Chiba, Kamogawa, Japan
    - 1237.19.81031 Boehringer Ingelheim Investigational Site
  - Fukui, Fukui, Japan
    - 1237.19.81061 Boehringer Ingelheim Investigational Site
  - Fukuoka, Fukuoka, Japan
    - 1237.19.81116 Boehringer Ingelheim Investigational Site
  - Fukuoka, Kitakyushu-city, Japan
    - 1237.19.81112 Boehringer Ingelheim Investigational Site
  - Fukuoka, Koga, Japan
    - 1237.19.81113 Boehringer Ingelheim Investigational Site
  - Fukuoka, Kurume, Japan
    - 1237.19.81111 Boehringer Ingelheim Investigational Site
  - Fukuoka, Yanagawa, Japan
    - 1237.19.81114 Boehringer Ingelheim Investigational Site
  - Fukuoka, Yukuhashi, Japan
    - 1237.19.81115 Boehringer Ingelheim Investigational Site
  - Fukushima, Fukushima, Japan
    - 1237.19.81022 Boehringer Ingelheim Investigational Site
  - Gifu, Mizunami, Japan
    - 1237.19.81066 Boehringer Ingelheim Investigational Site
  - Gifu, Ogaki, Japan
    - 1237.19.81065 Boehringer Ingelheim Investigational Site
  - Gunma, Fujioka, Japan
    - 1237.19.81025 Boehringer Ingelheim Investigational Site
  - Gunma, Maebashi, Japan
    - 1237.19.81027 Boehringer Ingelheim Investigational Site
  - Gunma, Takasaki, Japan
    - 1237.19.81026 Boehringer Ingelheim Investigational Site
  - Hiroshima, Fukuyama, Japan
    - 1237.19.81101 Boehringer Ingelheim Investigational Site
  - Hiroshima, Hiroshima, Japan
    - 1237.19.81104 Boehringer Ingelheim Investigational Site
  - Hiroshima, Kure, Japan
    - 1237.19.81102 Boehringer Ingelheim Investigational Site
  - Hiroshima, Kure, Japan
    - 1237.19.81103 Boehringer Ingelheim Investigational Site
  - Hokkaido, Asahikawa, Japan
    - 1237.19.81010 Boehringer Ingelheim Investigational Site
  - Hokkaido, Chitose, Japan
    - 1237.19.81007 Boehringer Ingelheim Investigational Site
  - Hokkaido, Hakodate, Japan
    - 1237.19.81012 Boehringer Ingelheim Investigational Site
  - Hokkaido, Hakodate, Japan
    - 1237.19.81013 Boehringer Ingelheim Investigational Site
  - Hokkaido, Obihiro, Japan
    - 1237.19.81009 Boehringer Ingelheim Investigational Site
  - Hokkaido, Obihiro, Japan
    - 1237.19.81015 Boehringer Ingelheim Investigational Site
  - Hokkaido, Otaru, Japan
    - 1237.19.81016 Boehringer Ingelheim Investigational Site
  - Hokkaido, Sapporo, Japan
    - 1237.19.81001 Boehringer Ingelheim Investigational Site
  - Hokkaido, Sapporo, Japan
    - 1237.19.81002 Boehringer Ingelheim Investigational Site
  - Hokkaido, Sapporo, Japan
    - 1237.19.81004 Boehringer Ingelheim Investigational Site
  - Hokkaido, Sapporo, Japan
    - 1237.19.81006 Boehringer Ingelheim Investigational Site
  - Hokkaido, Sapporo, Japan
    - 1237.19.81008 Boehringer Ingelheim Investigational Site
  - Hokkaido, Sapporo, Japan
    - 1237.19.81011 Boehringer Ingelheim Investigational Site
  - Hokkaido, Sapporo, Japan
    - 1237.19.81014 Boehringer Ingelheim Investigational Site
  - Hokkaido, Sapporo, Japan
    - 1237.19.81017 Boehringer Ingelheim Investigational Site
  - Hokkaido, Tomakomai, Japan
    - 1237.19.81003 Boehringer Ingelheim Investigational Site
  - Hyogo, Himeji, Japan
    - 1237.19.81090 Boehringer Ingelheim Investigational Site
  - Hyogo, Himeji, Japan
    - 1237.19.81093 Boehringer Ingelheim Investigational Site
  - Hyogo, Kobe, Japan
    - 1237.19.81091 Boehringer Ingelheim Investigational Site
  - Hyogo, Nishinomiya, Japan
    - 1237.19.81092 Boehringer Ingelheim Investigational Site
  - Ibaraki, Hitachinaka, Japan
    - 1237.19.81024 Boehringer Ingelheim Investigational Site
  - Ibaraki, Inashiki-gun, Japan
    - 1237.19.81129 Boehringer Ingelheim Investigational Site
  - Ibaraki, Naka-gun, Japan
    - 1237.19.81023 Boehringer Ingelheim Investigational Site
  - Ishikawa, Kanazawa, Japan
    - 1237.19.81060 Boehringer Ingelheim Investigational Site
  - Iwate, Morioka, Japan
    - 1237.19.81018 Boehringer Ingelheim Investigational Site
  - Kagawa, Sakaide, Japan
    - 1237.19.81108 Boehringer Ingelheim Investigational Site
  - Kagawa, Takamatsu, Japan
    - 1237.19.81107 Boehringer Ingelheim Investigational Site
  - Kagawa, Takamatsu, Japan
    - 1237.19.81109 Boehringer Ingelheim Investigational Site
  - Kagoshima, Kagoshima, Japan
    - 1237.19.81118 Boehringer Ingelheim Investigational Site
  - Kanagawa, Isehara, Japan
    - 1237.19.81050 Boehringer Ingelheim Investigational Site
  - Kanagawa, Kawasaki, Japan
    - 1237.19.81052 Boehringer Ingelheim Investigational Site
  - Kanagawa, Kawasaki, Japan
    - 1237.19.81053 Boehringer Ingelheim Investigational Site
  - Kanagawa, Kawasaki, Japan
    - 1237.19.81055 Boehringer Ingelheim Investigational Site
  - Kanagawa, Sagamihara, Japan
    - 1237.19.81054 Boehringer Ingelheim Investigational Site
  - Kanagawa, Sagamihara, Japan
    - 1237.19.81056 Boehringer Ingelheim Investigational Site
  - Kanagawa, Yokohama, Japan
    - 1237.19.81049 Boehringer Ingelheim Investigational Site
  - Kanagawa, Yokohama, Japan
    - 1237.19.81051 Boehringer Ingelheim Investigational Site
  - Kochi, Kochi, Japan
    - 1237.19.81110 Boehringer Ingelheim Investigational Site
  - Kochi, Nankoku, Japan
    - 1237.19.81130 Boehringer Ingelheim Investigational Site
  - Kyoto, Kyoto, Japan
    - 1237.19.81077 Boehringer Ingelheim Investigational Site
  - Mie, Matsusaka, Japan
    - 1237.19.81076 Boehringer Ingelheim Investigational Site
  - Miyagi, Sendai, Japan
    - 1237.19.81005 Boehringer Ingelheim Investigational Site
  - Miyagi, Sendai, Japan
    - 1237.19.81019 Boehringer Ingelheim Investigational Site
  - Miyagi, Sendai, Japan
    - 1237.19.81020 Boehringer Ingelheim Investigational Site
  - Miyagi, Sendai, Japan
    - 1237.19.81038 Boehringer Ingelheim Investigational Site
  - Nagano, Matsumoto, Japan
    - 1237.19.81064 Boehringer Ingelheim Investigational Site
  - Nagano, Matumoto, Japan
    - 1237.19.81063 Boehringer Ingelheim Investigational Site
  - Nagasaki, Isahaya, Japan
    - 1237.19.81117 Boehringer Ingelheim Investigational Site
  - Nara, Ikoma, Japan
    - 1237.19.81095 Boehringer Ingelheim Investigational Site
  - Niigata, Niigata, Japan
    - 1237.19.81057 Boehringer Ingelheim Investigational Site
  - Niigata, Niigata, Japan
    - 1237.19.81058 Boehringer Ingelheim Investigational Site
  - Niigata, Niigata, Japan
    - 1237.19.81059 Boehringer Ingelheim Investigational Site
  - Okayama, Japan
    - 1237.19.81125 Boehringer Ingelheim Investigational Site
  - Okayama, Okayama, Japan
    - 1237.19.81100 Boehringer Ingelheim Investigational Site
  - Okinawa, Urasoe, Japan
    - 1237.19.81119 Boehringer Ingelheim Investigational Site
  - Okinawa, Uruma, Japan
    - 1237.19.81120 Boehringer Ingelheim Investigational Site
  - Osaka, Ikeda, Japan
    - 1237.19.81089 Boehringer Ingelheim Investigational Site
  - Osaka, Kishiwada, Japan
    - 1237.19.81082 Boehringer Ingelheim Investigational Site
  - Osaka, Osaka, Japan
    - 1237.19.81079 Boehringer Ingelheim Investigational Site
  - Osaka, Osaka, Japan
    - 1237.19.81080 Boehringer Ingelheim Investigational Site
  - Osaka, Osaka, Japan
    - 1237.19.81086 Boehringer Ingelheim Investigational Site
  - Osaka, Osaka, Japan
    - 1237.19.81088 Boehringer Ingelheim Investigational Site
  - Osaka, Osakasayama, Japan
    - 1237.19.81078 Boehringer Ingelheim Investigational Site
  - Osaka, Sakai, Japan
    - 1237.19.81083 Boehringer Ingelheim Investigational Site
  - Osaka, Takatsuki, Japan
    - 1237.19.81081 Boehringer Ingelheim Investigational Site
  - Osaka, Toyonaka, Japan
    - 1237.19.81085 Boehringer Ingelheim Investigational Site
  - Osaka, Yao, Japan
    - 1237.19.81087 Boehringer Ingelheim Investigational Site
  - Saitama, Koshigaya, Japan
    - 1237.19.81028 Boehringer Ingelheim Investigational Site
  - Saitama, Saitama, Japan
    - 1237.19.81029 Boehringer Ingelheim Investigational Site
  - Shiga, Japan
    - 1237.19.81128 Boehringer Ingelheim Investigational Site
  - Shimane, Izumo, Japan
    - 1237.19.81098 Boehringer Ingelheim Investigational Site
  - Shimane, Izumo, Japan
    - 1237.19.81099 Boehringer Ingelheim Investigational Site
  - Shizuoka, Hamamatsu, Japan
    - 1237.19.81067 Boehringer Ingelheim Investigational Site
  - Shizuoka, Shizuoka, Japan
    - 1237.19.81068 Boehringer Ingelheim Investigational Site
  - Tochigi, Shimotsuke, Japan
    - 1237.19.81123 Boehringer Ingelheim Investigational Site
  - Tokyo, Japan
    - 1237.19.81126 Boehringer Ingelheim Investigational Site
  - Tokyo,, Japan
    - 1237.19.81122 Boehringer Ingelheim Investigational Site
  - Tokyo, Chiyoda-ku, Japan
    - 1237.19.81075 Boehringer Ingelheim Investigational Site
  - Tokyo, Chuo-ku, Japan
    - 1237.19.81036 Boehringer Ingelheim Investigational Site
  - Tokyo, Chuo-ku, Japan
    - 1237.19.81040 Boehringer Ingelheim Investigational Site
  - Tokyo, Hachioji, Japan
    - 1237.19.81039 Boehringer Ingelheim Investigational Site
  - Tokyo, Itabashi-ku, Japan
    - 1237.19.81035 Boehringer Ingelheim Investigational Site
  - Tokyo, Itabashi-ku, Japan
    - 1237.19.81043 Boehringer Ingelheim Investigational Site
  - Tokyo, Koto-ku, Japan
    - 1237.19.81046 Boehringer Ingelheim Investigational Site
  - Tokyo, Meguro-ku, Japan
    - 1237.19.81034 Boehringer Ingelheim Investigational Site
  - Tokyo, Minato-ku, Japan
    - 1237.19.81032 Boehringer Ingelheim Investigational Site
  - Tokyo, Shinagawa-ku, Japan
    - 1237.19.81047 Boehringer Ingelheim Investigational Site
  - Tokyo, Shinjuku-ku, Japan
    - 1237.19.81033 Boehringer Ingelheim Investigational Site
  - Tokyo, Shinjuku-ku, Japan
    - 1237.19.81041 Boehringer Ingelheim Investigational Site
  - Tokyo, Shinjuku-ku, Japan
    - 1237.19.81042 Boehringer Ingelheim Investigational Site
  - Tokyo, Tachikawa, Japan
    - 1237.19.81044 Boehringer Ingelheim Investigational Site
  - Tokyo, Toshima-ku, Japan
    - 1237.19.81048 Boehringer Ingelheim Investigational Site
  - Wakayama, Hidaka-gun, Japan
    - 1237.19.81097 Boehringer Ingelheim Investigational Site
  - Wakayama, Wakayama, Japan
    - 1237.19.81096 Boehringer Ingelheim Investigational Site
  - Yamagata,, Japan
    - 1237.19.81124 Boehringer Ingelheim Investigational Site
  - Yamagata, Yonezawa, Japan
    - 1237.19.81021 Boehringer Ingelheim Investigational Site
  - Yamaguchi, Iwakuni, Japan
    - 1237.19.81106 Boehringer Ingelheim Investigational Site
  - Yamaguchi, Ube, Japan
    - 1237.19.81105 Boehringer Ingelheim Investigational Site
  - Yamanashi, Kofu, Japan
    - 1237.19.81062 Boehringer Ingelheim Investigational Site
Korea, Republic of
- - Bucheon, Korea, Republic of
    - 1237.19.82004 Boehringer Ingelheim Investigational Site
  - Goyang, Korea, Republic of
    - 1237.19.82009 Boehringer Ingelheim Investigational Site
  - Gwangju, Korea, Republic of
    - 1237.19.82006 Boehringer Ingelheim Investigational Site
  - Seoul, Korea, Republic of
    - 1237.19.82001 Boehringer Ingelheim Investigational Site
  - Seoul, Korea, Republic of
    - 1237.19.82002 Boehringer Ingelheim Investigational Site
  - Seoul, Korea, Republic of
    - 1237.19.82005 Boehringer Ingelheim Investigational Site
  - Seoul, Korea, Republic of
    - 1237.19.82007 Boehringer Ingelheim Investigational Site
  - Seoul, Korea, Republic of
    - 1237.19.82008 Boehringer Ingelheim Investigational Site
  - Seoul, Korea, Republic of
    - 1237.19.82010 Boehringer Ingelheim Investigational Site
  - Wonju, Korea, Republic of
    - 1237.19.82003 Boehringer Ingelheim Investigational Site
Latvia
- - Daugavpils, Latvia
    - 1237.19.37103 Boehringer Ingelheim Investigational Site
  - Riga, Latvia
    - 1237.19.37101 Boehringer Ingelheim Investigational Site
  - Riga, Latvia
    - 1237.19.37105 Boehringer Ingelheim Investigational Site
  - Riga, Latvia
    - 1237.19.37106 Boehringer Ingelheim Investigational Site
  - Tukums, Latvia
    - 1237.19.37104 Boehringer Ingelheim Investigational Site
  - Valmiera, Latvia
    - 1237.19.37102 Boehringer Ingelheim Investigational Site
Lithuania
- - Kaunas, Lithuania
    - 1237.19.37002 Boehringer Ingelheim Investigational Site
  - Klaipeda, Lithuania
    - 1237.19.37003 Boehringer Ingelheim Investigational Site
  - Klaipeda, Lithuania
    - 1237.19.37004 Boehringer Ingelheim Investigational Site
  - Vilnius, Lithuania
    - 1237.19.37001 Boehringer Ingelheim Investigational Site
Malaysia
- - Kota Bahru, Malaysia
    - 1237.19.60006 Boehringer Ingelheim Investigational Site
  - Kuala Lumpur, Malaysia
    - 1237.19.60002 Boehringer Ingelheim Investigational Site
  - Kuala Terengganu, Malaysia
    - 1237.19.60004 Boehringer Ingelheim Investigational Site
  - Kuching, Malaysia
    - 1237.19.60001 Boehringer Ingelheim Investigational Site
Mexico
- - Aguascalientes, Mexico
    - 1237.19.52006 Boehringer Ingelheim Investigational Site
  - Guadalajara, Mexico
    - 1237.19.52007 Boehringer Ingelheim Investigational Site
  - León, Mexico
    - 1237.19.52005 Boehringer Ingelheim Investigational Site
  - Monterrey, Mexico
    - 1237.19.52001 Boehringer Ingelheim Investigational Site
  - México, Mexico
    - 1237.19.52003 Boehringer Ingelheim Investigational Site
  - Tijuana, Mexico
    - 1237.19.52004 Boehringer Ingelheim Investigational Site
Netherlands
- - Alkmaar, Netherlands
    - 1237.19.31017 Boehringer Ingelheim Investigational Site
  - Almelo, Netherlands
    - 1237.19.31015 Boehringer Ingelheim Investigational Site
  - Amsterdam, Netherlands
    - 1237.19.31011 Boehringer Ingelheim Investigational Site
  - Assen, Netherlands
    - 1237.19.31014 Boehringer Ingelheim Investigational Site
  - Breda, Netherlands
    - 1237.19.31001 Boehringer Ingelheim Investigational Site
  - EDE, Netherlands
    - 1237.19.31003 Boehringer Ingelheim Investigational Site
  - Eindhoven, Netherlands
    - 1237.19.31002 Boehringer Ingelheim Investigational Site
  - Groningen, Netherlands
    - 1237.19.31005 Boehringer Ingelheim Investigational Site
  - Harderwijk, Netherlands
    - 1237.19.31010 Boehringer Ingelheim Investigational Site
  - Hoofddorp, Netherlands
    - 1237.19.31012 Boehringer Ingelheim Investigational Site
  - Hoorn, Netherlands
    - 1237.19.31013 Boehringer Ingelheim Investigational Site
  - Leeuwarden, Netherlands
    - 1237.19.31018 Boehringer Ingelheim Investigational Site
  - Leiden, Netherlands
    - 1237.19.31016 Boehringer Ingelheim Investigational Site
  - Rotterdam, Netherlands
    - 1237.19.31008 Boehringer Ingelheim Investigational Site
  - Sittard - Geleen, Netherlands
    - 1237.19.31007 Boehringer Ingelheim Investigational Site
  - Zutphen, Netherlands
    - 1237.19.31004 Boehringer Ingelheim Investigational Site
New Zealand
- - Auckland, New Zealand, New Zealand
    - 1237.19.64003 Boehringer Ingelheim Investigational Site
  - Christchurch, New Zealand
    - 1237.19.64002 Boehringer Ingelheim Investigational Site
  - Christchurch Central, New Zealand
    - 1237.19.64004 Boehringer Ingelheim Investigational Site
  - Dunedin, New Zealand
    - 1237.19.64007 Boehringer Ingelheim Investigational Site
  - Dunedin, New Zealand
    - 1237.19.64008 Boehringer Ingelheim Investigational Site
  - Greenlane East Auckland NZ, New Zealand
    - 1237.19.64001 Boehringer Ingelheim Investigational Site
  - Hamilton, New Zealand
    - 1237.19.64005 Boehringer Ingelheim Investigational Site
  - Tauranga, New Zealand
    - 1237.19.64009 Boehringer Ingelheim Investigational Site
Norway
- - Arendal, Norway
    - 1237.19.47002 Boehringer Ingelheim Investigational Site
  - Hamar, Norway
    - 1237.19.47008 Boehringer Ingelheim Investigational Site
  - Hønefoss, Norway
    - 1237.19.47001 Boehringer Ingelheim Investigational Site
  - Kløfta, Norway
    - 1237.19.47006 Boehringer Ingelheim Investigational Site
  - Lierskogen, Norway
    - 1237.19.47007 Boehringer Ingelheim Investigational Site
  - Oslo, Norway
    - 1237.19.47004 Boehringer Ingelheim Investigational Site
  - Skedsmokorset, Norway
    - 1237.19.47005 Boehringer Ingelheim Investigational Site
Philippines
- - Angeles City, Philippines
    - 1237.19.63007 Boehringer Ingelheim Investigational Site
  - Cebu City, Philippines
    - 1237.19.63001 Boehringer Ingelheim Investigational Site
  - Dasmarinas, Philippines
    - 1237.19.63003 Boehringer Ingelheim Investigational Site
  - Davao City, Philippines
    - 1237.19.63008 Boehringer Ingelheim Investigational Site
  - Iloilo, Philippines
    - 1237.19.63006 Boehringer Ingelheim Investigational Site
  - Manila, Philippines
    - 1237.19.63005 Boehringer Ingelheim Investigational Site
  - Quezon City, Philippines
    - 1237.19.63002 Boehringer Ingelheim Investigational Site
Poland
- - Bialystok, Poland
    - 1237.19.48009 Boehringer Ingelheim Investigational Site
  - Bialystok, Poland
    - 1237.19.48026 Boehringer Ingelheim Investigational Site
  - Bialystok, Poland
    - 1237.19.48031 Boehringer Ingelheim Investigational Site
  - Bydgoszcz, Poland
    - 1237.19.48010 Boehringer Ingelheim Investigational Site
  - Chojnice, Poland
    - 1237.19.48029 Boehringer Ingelheim Investigational Site
  - Katowice, Poland
    - 1237.19.48001 Boehringer Ingelheim Investigational Site
  - Kielce, Poland
    - 1237.19.48024 Boehringer Ingelheim Investigational Site
  - Krakow, Poland
    - 1237.19.48005 Boehringer Ingelheim Investigational Site
  - Krakow, Poland
    - 1237.19.48007 Boehringer Ingelheim Investigational Site
  - Libiaz, Poland
    - 1237.19.48015 Boehringer Ingelheim Investigational Site
  - Lodz, Poland
    - 1237.19.48006 Boehringer Ingelheim Investigational Site
  - Lodz, Poland
    - 1237.19.48008 Boehringer Ingelheim Investigational Site
  - Lublin, Poland
    - 1237.19.48025 Boehringer Ingelheim Investigational Site
  - Olsztyn, Poland
    - 1237.19.48011 Boehringer Ingelheim Investigational Site
  - Ostow Wielkopolski, Poland
    - 1237.19.48013 Boehringer Ingelheim Investigational Site
  - Ostroda, Poland
    - 1237.19.48019 Boehringer Ingelheim Investigational Site
  - Piaseczno, Poland
    - 1237.19.48020 Boehringer Ingelheim Investigational Site
  - Poznan, Poland
    - 1237.19.48002 Boehringer Ingelheim Investigational Site
  - Poznan, Poland
    - 1237.19.48004 Boehringer Ingelheim Investigational Site
  - Poznan, Poland
    - 1237.19.48014 Boehringer Ingelheim Investigational Site
  - Skierniewice, Poland
    - 1237.19.48016 Boehringer Ingelheim Investigational Site
  - Swidnik, Poland
    - 1237.19.48021 Boehringer Ingelheim Investigational Site
  - Szczecin, Poland
    - 1237.19.48017 Boehringer Ingelheim Investigational Site
  - Tarnobrzeg, Poland
    - 1237.19.48030 Boehringer Ingelheim Investigational Site
  - Warszawa, Poland
    - 1237.19.48022 Boehringer Ingelheim Investigational Site
  - Wolomin, Poland
    - 1237.19.48003 Boehringer Ingelheim Investigational Site
  - Wroclaw, Poland
    - 1237.19.48023 Boehringer Ingelheim Investigational Site
  - Zawadzkie, Poland
    - 1237.19.48018 Boehringer Ingelheim Investigational Site
  - Zgierz, Poland
    - 1237.19.48012 Boehringer Ingelheim Investigational Site
Portugal
- - Almada, Portugal
    - 1237.19.35010 Boehringer Ingelheim Investigational Site
  - Amadora, Portugal
    - 1237.19.35005 Boehringer Ingelheim Investigational Site
  - Aveiro, Portugal
    - 1237.19.35008 Boehringer Ingelheim Investigational Site
  - Braga, Portugal
    - 1237.19.35009 Boehringer Ingelheim Investigational Site
  - Coimbra, Portugal
    - 1237.19.35001 Boehringer Ingelheim Investigational Site
  - Guimarães, Portugal
    - 1237.19.35012 Boehringer Ingelheim Investigational Site
  - Lisboa, Portugal
    - 1237.19.35002 Boehringer Ingelheim Investigational Site
  - Lisboa, Portugal
    - 1237.19.35004 Boehringer Ingelheim Investigational Site
  - Porto, Portugal
    - 1237.19.35003 Boehringer Ingelheim Investigational Site
  - Vila Nova de Gaia, Portugal
    - 1237.19.35006 Boehringer Ingelheim Investigational Site
Romania
- - Bragadiru, Romania
    - 1237.19.40007 Boehringer Ingelheim Investigational Site
  - Bucharest, Romania
    - 1237.19.40003 Boehringer Ingelheim Investigational Site
  - Bucharest, Romania
    - 1237.19.40004 Boehringer Ingelheim Investigational Site
  - Bucharest, Romania
    - 1237.19.40005 Boehringer Ingelheim Investigational Site
  - Bucharest, Romania
    - 1237.19.40008 Boehringer Ingelheim Investigational Site
  - Constanta, Romania
    - 1237.19.40002 Boehringer Ingelheim Investigational Site
  - Timisoara, Romania
    - 1237.19.40006 Boehringer Ingelheim Investigational Site
Russian Federation
- - Arkhangelsk, Russian Federation
    - 1237.19.70004 Boehringer Ingelheim Investigational Site
  - Barnaul, Russian Federation
    - 1237.19.70028 Boehringer Ingelheim Investigational Site
  - Chelyabinsk, Russian Federation
    - 1237.19.70017 Boehringer Ingelheim Investigational Site
  - Ekaterinburg, Russian Federation
    - 1237.19.70020 Boehringer Ingelheim Investigational Site
  - Gatchina, Russian Federation
    - 1237.19.70014 Boehringer Ingelheim Investigational Site
  - Ivanovo, Russian Federation
    - 1237.19.70051 Boehringer Ingelheim Investigational Site
  - Kazan, Russian Federation
    - 1237.19.70050 Boehringer Ingelheim Investigational Site
  - Kemerovo, Russian Federation
    - 1237.19.70006 Boehringer Ingelheim Investigational Site
  - Kemerovo, Russian Federation
    - 1237.19.70023 Boehringer Ingelheim Investigational Site
  - Kirov, Russian Federation
    - 1237.19.70031 Boehringer Ingelheim Investigational Site
  - Lomonosov, Russian Federation
    - 1237.19.70007 Boehringer Ingelheim Investigational Site
  - Moscow, Russian Federation
    - 1237.19.70002 Boehringer Ingelheim Investigational Site
  - Moscow, Russian Federation
    - 1237.19.70003 Boehringer Ingelheim Investigational Site
  - Moscow, Russian Federation
    - 1237.19.70032 Boehringer Ingelheim Investigational Site
  - Moscow, Russian Federation
    - 1237.19.70047 Boehringer Ingelheim Investigational Site
  - Novosibirsk, Russian Federation
    - 1237.19.70024 Boehringer Ingelheim Investigational Site
  - Novosibirsk, Russian Federation
    - 1237.19.70025 Boehringer Ingelheim Investigational Site
  - Novosibirsk, Russian Federation
    - 1237.19.70034 Boehringer Ingelheim Investigational Site
  - Omsk, Russian Federation
    - 1237.19.70035 Boehringer Ingelheim Investigational Site
  - Penza, Russian Federation
    - 1237.19.70033 Boehringer Ingelheim Investigational Site
  - Pskov, Russian Federation
    - 1237.19.70021 Boehringer Ingelheim Investigational Site
  - Rosto-on-Don, Russian Federation
    - 1237.19.70052 Boehringer Ingelheim Investigational Site
  - Rostov-na-Donu, Russian Federation
    - 1237.19.70015 Boehringer Ingelheim Investigational Site
  - Saratov, Russian Federation
    - 1237.19.70005 Boehringer Ingelheim Investigational Site
  - Saratov, Russian Federation
    - 1237.19.70040 Boehringer Ingelheim Investigational Site
  - Saratov, Russian Federation
    - 1237.19.70044 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70009 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70010 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70011 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70012 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70018 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70019 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70022 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70038 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70041 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70042 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70046 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70048 Boehringer Ingelheim Investigational Site
  - St. Petersburg, Russian Federation
    - 1237.19.70049 Boehringer Ingelheim Investigational Site
  - Tomsk, Russian Federation
    - 1237.19.70008 Boehringer Ingelheim Investigational Site
  - Tomsk, Russian Federation
    - 1237.19.70026 Boehringer Ingelheim Investigational Site
  - Ulyanovsk, Russian Federation
    - 1237.19.70037 Boehringer Ingelheim Investigational Site
  - Volgograd, Russian Federation
    - 1237.19.70030 Boehringer Ingelheim Investigational Site
  - Yaroslavl, Russian Federation
    - 1237.19.70036 Boehringer Ingelheim Investigational Site
Serbia
- - Belgrade, Serbia
    - 1237.19.38101 Boehringer Ingelheim Investigational Site
  - Belgrade, Serbia
    - 1237.19.38102 Boehringer Ingelheim Investigational Site
  - Belgrade, Serbia
    - 1237.19.38105 Boehringer Ingelheim Investigational Site
  - Belgrade, Serbia
    - 1237.19.38107 Boehringer Ingelheim Investigational Site
  - Kragujevac, Serbia
    - 1237.19.38104 Boehringer Ingelheim Investigational Site
  - Nis, Serbia
    - 1237.19.38108 Boehringer Ingelheim Investigational Site
  - Sombor, Serbia
    - 1237.19.38106 Boehringer Ingelheim Investigational Site
  - Sremska Kamenica, Serbia
    - 1237.19.38103 Boehringer Ingelheim Investigational Site
Singapore
- - Singapore, Singapore
    - 1237.19.65001 Boehringer Ingelheim Investigational Site
  - Singapore, Singapore
    - 1237.19.65002 Boehringer Ingelheim Investigational Site
Slovakia
- - Bratislava, Slovakia
    - 1237.19.42101 Boehringer Ingelheim Investigational Site
  - Humenne, Slovakia
    - 1237.19.42104 Boehringer Ingelheim Investigational Site
  - Kosice, Slovakia
    - 1237.19.42102 Boehringer Ingelheim Investigational Site
  - Martin, Slovakia
    - 1237.19.42106 Boehringer Ingelheim Investigational Site
  - Poprad, Slovakia
    - 1237.19.42107 Boehringer Ingelheim Investigational Site
  - Spisska Nova Ves, Slovakia
    - 1237.19.42103 Boehringer Ingelheim Investigational Site
  - Vrable, Slovakia
    - 1237.19.42105 Boehringer Ingelheim Investigational Site
Slovenia
- - Golnik, Slovenia
    - 1237.19.38601 Boehringer Ingelheim Investigational Site
  - Pohorje, Slovenia
    - 1237.19.38603 Boehringer Ingelheim Investigational Site
  - Topolsica, Slovenia
    - 1237.19.38602 Boehringer Ingelheim Investigational Site
South Africa
- - Amanzimtoti, South Africa
    - 1237.19.27006 Boehringer Ingelheim Investigational Site
  - Cape Town, South Africa
    - 1237.19.27001 Boehringer Ingelheim Investigational Site
  - Cape Town, South Africa
    - 1237.19.27002 Boehringer Ingelheim Investigational Site
  - Cape Town, South Africa
    - 1237.19.27003 Boehringer Ingelheim Investigational Site
  - Cape Town, South Africa
    - 1237.19.27007 Boehringer Ingelheim Investigational Site
  - Cape Town, South Africa
    - 1237.19.27009 Boehringer Ingelheim Investigational Site
  - Morningside, Sandton, South Africa
    - 1237.19.27011 Boehringer Ingelheim Investigational Site
  - Parow, South Africa
    - 1237.19.27010 Boehringer Ingelheim Investigational Site
  - Pretoria, South Africa
    - 1237.19.27004 Boehringer Ingelheim Investigational Site
  - Pretoria, South Africa
    - 1237.19.27008 Boehringer Ingelheim Investigational Site
Spain
- - Alicante, Spain
    - 1237.19.34017 Boehringer Ingelheim Investigational Site
  - Aranjuez, Spain
    - 1237.19.34025 Boehringer Ingelheim Investigational Site
  - Badalona, Spain
    - 1237.19.34024 Boehringer Ingelheim Investigational Site
  - Barakaldo (Bilbao), Spain
    - 1237.19.34011 Boehringer Ingelheim Investigational Site
  - Barcelona, Spain
    - 1237.19.34012 Boehringer Ingelheim Investigational Site
  - Barcelona, Spain
    - 1237.19.34021 Boehringer Ingelheim Investigational Site
  - Centelles, Spain
    - 1237.19.34028 Boehringer Ingelheim Investigational Site
  - Cáceres, Spain
    - 1237.19.34007 Boehringer Ingelheim Investigational Site
  - Girona, Spain
    - 1237.19.34015 Boehringer Ingelheim Investigational Site
  - Granollers (Barcelona), Spain
    - 1237.19.34027 Boehringer Ingelheim Investigational Site
  - L'Hospitalet Llobregat (bcn), Spain
    - 1237.19.34003 Boehringer Ingelheim Investigational Site
  - Liencres (Pielagos), Spain
    - 1237.19.34001 Boehringer Ingelheim Investigational Site
  - Madrid, Spain
    - 1237.19.34005 Boehringer Ingelheim Investigational Site
  - Madrid, Spain
    - 1237.19.34020 Boehringer Ingelheim Investigational Site
  - Malaga, Spain
    - 1237.19.34009 Boehringer Ingelheim Investigational Site
  - Mérida, Spain
    - 1237.19.34019 Boehringer Ingelheim Investigational Site
  - Palma de Mallorca, Spain
    - 1237.19.34013 Boehringer Ingelheim Investigational Site
  - Pamplona, Spain
    - 1237.19.34004 Boehringer Ingelheim Investigational Site
  - Pozuelo de Alarcón, Spain
    - 1237.19.34018 Boehringer Ingelheim Investigational Site
  - Sabadell, Spain
    - 1237.19.34023 Boehringer Ingelheim Investigational Site
  - Sevilla, Spain
    - 1237.19.34014 Boehringer Ingelheim Investigational Site
  - Valencia, Spain
    - 1237.19.34006 Boehringer Ingelheim Investigational Site
  - Valladolid, Spain
    - 1237.19.34029 Boehringer Ingelheim Investigational Site
  - Vic, Spain
    - 1237.19.34026 Boehringer Ingelheim Investigational Site
  - Vilanova i la Geltrú, Spain
    - 1237.19.34022 Boehringer Ingelheim Investigational Site
  - Zaragoza, Spain
    - 1237.19.34002 Boehringer Ingelheim Investigational Site
Sweden
- - Göteborg, Sweden
    - 1237.19.46002 Boehringer Ingelheim Investigational Site
  - Härnösand, Sweden
    - 1237.19.46008 Boehringer Ingelheim Investigational Site
  - Höllviken, Sweden
    - 1237.19.46004 Boehringer Ingelheim Investigational Site
  - Lund, Sweden
    - 1237.19.46001 Boehringer Ingelheim Investigational Site
  - Rättvik, Sweden
    - 1237.19.46005 Boehringer Ingelheim Investigational Site
  - Stockholm, Sweden
    - 1237.19.46007 Boehringer Ingelheim Investigational Site
Switzerland
- - Ascona, Switzerland
    - 1237.19.41004 Boehringer Ingelheim Investigational Site
  - Bern, Switzerland
    - 1237.19.41002 Boehringer Ingelheim Investigational Site
  - Liestal, Switzerland
    - 1237.19.41001 Boehringer Ingelheim Investigational Site
Taiwan
- - Kaohsiung, Taiwan
    - 1237.19.88010 Boehringer Ingelheim Investigational Site
  - Kaohsiung, Taiwan
    - 1237.19.88011 Boehringer Ingelheim Investigational Site
  - Kaohsiung City, Taiwan
    - 1237.19.88012 Boehringer Ingelheim Investigational Site
  - New Taipei, Taiwan
    - 1237.19.88004 Boehringer Ingelheim Investigational Site
  - New Taipei City, Taiwan
    - 1237.19.88009 Boehringer Ingelheim Investigational Site
  - Taipei, Taiwan
    - 1237.19.88001 Boehringer Ingelheim Investigational Site
  - Taipei, Taiwan
    - 1237.19.88005 Boehringer Ingelheim Investigational Site
  - Taipei, Taiwan
    - 1237.19.88008 Boehringer Ingelheim Investigational Site
  - Taipei, Taiwan
    - 1237.19.88013 Boehringer Ingelheim Investigational Site
  - Taipei City, Taiwan
    - 1237.19.88007 Boehringer Ingelheim Investigational Site
Thailand
- - Dusit, Thailand
    - 1237.19.66008 Boehringer Ingelheim Investigational Site
  - Hat Yai, Thailand
    - 1237.19.66005 Boehringer Ingelheim Investigational Site
  - Maerim, Thailand
    - 1237.19.66003 Boehringer Ingelheim Investigational Site
  - Muang, Thailand
    - 1237.19.66001 Boehringer Ingelheim Investigational Site
  - Muang, Thailand
    - 1237.19.66002 Boehringer Ingelheim Investigational Site
  - Patumwan, Thailand
    - 1237.19.66007 Boehringer Ingelheim Investigational Site
  - Rajathevee, Thailand
    - 1237.19.66004 Boehringer Ingelheim Investigational Site
Turkey
- - Ankara, Turkey
    - 1237.19.90006 Boehringer Ingelheim Investigational Site
  - Ankara, Turkey
    - 1237.19.90007 Boehringer Ingelheim Investigational Site
  - Ankara, Turkey
    - 1237.19.90015 Boehringer Ingelheim Investigational Site
  - Ankara, Turkey
    - 1237.19.90016 Boehringer Ingelheim Investigational Site
  - Antalya, Turkey
    - 1237.19.90008 Boehringer Ingelheim Investigational Site
  - Bursa, Turkey
    - 1237.19.90010 Boehringer Ingelheim Investigational Site
  - Denizli, Turkey
    - 1237.19.90002 Boehringer Ingelheim Investigational Site
  - Istanbul, Turkey
    - 1237.19.90012 Boehringer Ingelheim Investigational Site
  - Istanbul, Turkey
    - 1237.19.90013 Boehringer Ingelheim Investigational Site
  - Istanbul, Turkey
    - 1237.19.90014 Boehringer Ingelheim Investigational Site
  - Izmir, Turkey
    - 1237.19.90003 Boehringer Ingelheim Investigational Site
  - Izmir, Turkey
    - 1237.19.90004 Boehringer Ingelheim Investigational Site
  - Izmir, Turkey
    - 1237.19.90005 Boehringer Ingelheim Investigational Site
  - Izmir, Turkey
    - 1237.19.90011 Boehringer Ingelheim Investigational Site
  - Kocaeli, Turkey
    - 1237.19.90001 Boehringer Ingelheim Investigational Site
  - Konya, Turkey
    - 1237.19.90009 Boehringer Ingelheim Investigational Site
  - Mersin, Turkey
    - 1237.19.90000 Boehringer Ingelheim Investigational Site
Ukraine
- - Ivano-Frankivsk, Ukraine
    - 1237.19.38009 Boehringer Ingelheim Investigational Site
  - Kharkiv, Ukraine
    - 1237.19.38001 Boehringer Ingelheim Investigational Site
  - Kiev, Ukraine
    - 1237.19.38005 Boehringer Ingelheim Investigational Site
  - Kiev, Ukraine
    - 1237.19.38007 Boehringer Ingelheim Investigational Site
  - Kyiv, Ukraine
    - 1237.19.38002 Boehringer Ingelheim Investigational Site
  - Kyiv, Ukraine
    - 1237.19.38003 Boehringer Ingelheim Investigational Site
  - Kyiv, Ukraine
    - 1237.19.38004 Boehringer Ingelheim Investigational Site
  - Kyiv, Ukraine
    - 1237.19.38006 Boehringer Ingelheim Investigational Site
  - Odesa, Ukraine
    - 1237.19.38010 Boehringer Ingelheim Investigational Site
  - Vinnytsya, Ukraine
    - 1237.19.38008 Boehringer Ingelheim Investigational Site
United Kingdom
- - Bedford, United Kingdom
    - 1237.19.44008 Boehringer Ingelheim Investigational Site
  - Birmingham, United Kingdom
    - 1237.19.44006 Boehringer Ingelheim Investigational Site
  - Bradford, United Kingdom
    - 1237.19.44001 Boehringer Ingelheim Investigational Site
  - Chertsey, United Kingdom
    - 1237.19.44002 Boehringer Ingelheim Investigational Site
  - Coventry, United Kingdom
    - 1237.19.44004 Boehringer Ingelheim Investigational Site
  - Doncaster, United Kingdom
    - 1237.19.44007 Boehringer Ingelheim Investigational Site
  - South Shields, United Kingdom
    - 1237.19.44003 Boehringer Ingelheim Investigational Site
United States
- Alabama
  - Andalusia, Alabama, United States
    - 1237.19.10039 Boehringer Ingelheim Investigational Site
  - Birmingham, Alabama, United States
    - 1237.19.10009 Boehringer Ingelheim Investigational Site
  - Florence, Alabama, United States
    - 1237.19.10077 Boehringer Ingelheim Investigational Site
  - Jasper, Alabama, United States
    - 1237.19.10115 Boehringer Ingelheim Investigational Site
- Arizona
  - Flagstaff, Arizona, United States
    - 1237.19.10069 Boehringer Ingelheim Investigational Site
  - Peoria, Arizona, United States
    - 1237.19.10085 Boehringer Ingelheim Investigational Site
- California
  - Lincoln, California, United States
    - 1237.19.10110 Boehringer Ingelheim Investigational Site
  - Los Angeles, California, United States
    - 1237.19.10118 Boehringer Ingelheim Investigational Site
  - Poway, California, United States
    - 1237.19.10074 Boehringer Ingelheim Investigational Site
- Colorado
  - Lafayette, Colorado, United States
    - 1237.19.10157 Boehringer Ingelheim Investigational Site
  - Wheat Ridge, Colorado, United States
    - 1237.19.10142 Boehringer Ingelheim Investigational Site
- Connecticut
  - Norwalk, Connecticut, United States
    - 1237.19.10133 Boehringer Ingelheim Investigational Site
  - Stamford, Connecticut, United States
    - 1237.19.10093 Boehringer Ingelheim Investigational Site
- Florida
  - Clearwater, Florida, United States
    - 1237.19.10029 Boehringer Ingelheim Investigational Site
  - Clearwater, Florida, United States
    - 1237.19.10106 Boehringer Ingelheim Investigational Site
  - Orlando, Florida, United States
    - 1237.19.10020 Boehringer Ingelheim Investigational Site
  - Saint Petersburg, Florida, United States
    - 1237.19.10000 Boehringer Ingelheim Investigational Site
  - Saint Petersburg, Florida, United States
    - 1237.19.10135 Boehringer Ingelheim Investigational Site
  - Tamarac, Florida, United States
    - 1237.19.10145 Boehringer Ingelheim Investigational Site
  - Tampa, Florida, United States
    - 1237.19.10066 Boehringer Ingelheim Investigational Site
  - Winter Park, Florida, United States
    - 1237.19.10032 Boehringer Ingelheim Investigational Site
- Georgia
  - Duluth, Georgia, United States
    - 1237.19.10080 Boehringer Ingelheim Investigational Site
  - Gainesville, Georgia, United States
    - 1237.19.10011 Boehringer Ingelheim Investigational Site
  - Lawrenceville, Georgia, United States
    - 1237.19.10112 Boehringer Ingelheim Investigational Site
- Idaho
  - Eagle, Idaho, United States
    - 1237.19.10037 Boehringer Ingelheim Investigational Site
- Illinois
  - O'Fallon, Illinois, United States
    - 1237.19.10130 Boehringer Ingelheim Investigational Site
  - River Forest, Illinois, United States
    - 1237.19.10065 Boehringer Ingelheim Investigational Site
- Indiana
  - Muncie, Indiana, United States
    - 1237.19.10122 Boehringer Ingelheim Investigational Site
- Kansas
  - Topeka, Kansas, United States
    - 1237.19.10063 Boehringer Ingelheim Investigational Site
- Kentucky
  - Bowling Green, Kentucky, United States
    - 1237.19.10048 Boehringer Ingelheim Investigational Site
  - Fort Mitchell, Kentucky, United States
    - 1237.19.10108 Boehringer Ingelheim Investigational Site
- Louisiana
  - New Orleans, Louisiana, United States
    - 1237.19.10109 Boehringer Ingelheim Investigational Site
  - Opelousas, Louisiana, United States
    - 1237.19.10095 Boehringer Ingelheim Investigational Site
  - Shreveport, Louisiana, United States
    - 1237.19.10113 Boehringer Ingelheim Investigational Site
  - Shreveport, Louisiana, United States
    - 1237.19.10139 Boehringer Ingelheim Investigational Site
- Maryland
  - Baltimore, Maryland, United States
    - 1237.19.10117 Boehringer Ingelheim Investigational Site
  - Columbia, Maryland, United States
    - 1237.19.10083 Boehringer Ingelheim Investigational Site
  - Hollywood, Maryland, United States
    - 1237.19.10072 Boehringer Ingelheim Investigational Site
- Massachusetts
  - Fall River, Massachusetts, United States
    - 1237.19.10027 Boehringer Ingelheim Investigational Site
  - North Dartmouth, Massachusetts, United States
    - 1237.19.10138 Boehringer Ingelheim Investigational Site
  - Worcester, Massachusetts, United States
    - 1237.19.10103 Boehringer Ingelheim Investigational Site
- Michigan
  - Ann Arbor, Michigan, United States
    - 1237.19.10075 Boehringer Ingelheim Investigational Site
  - Farmington Hills, Michigan, United States
    - 1237.19.10034 Boehringer Ingelheim Investigational Site
  - Traverse City, Michigan, United States
    - 1237.19.10082 Boehringer Ingelheim Investigational Site
- Minnesota
  - Fridley, Minnesota, United States
    - 1237.19.10043 Boehringer Ingelheim Investigational Site
  - Rochester, Minnesota, United States
    - 1237.19.10096 Boehringer Ingelheim Investigational Site
- Missouri
  - Chesterfield, Missouri, United States
    - 1237.19.10031 Boehringer Ingelheim Investigational Site
  - Saint Charles, Missouri, United States
    - 1237.19.10101 Boehringer Ingelheim Investigational Site
  - Saint Louis, Missouri, United States
    - 1237.19.10051 Boehringer Ingelheim Investigational Site
  - Saint Louis, Missouri, United States
    - 1237.19.10084 Boehringer Ingelheim Investigational Site
- Montana
  - Missoula, Montana, United States
    - 1237.19.10097 Boehringer Ingelheim Investigational Site
- Nevada
  - Reno, Nevada, United States
    - 1237.19.10060 Boehringer Ingelheim Investigational Site
- New Jersey
  - Marlton, New Jersey, United States
    - 1237.19.10081 Boehringer Ingelheim Investigational Site
- New York
  - Brooklyn, New York, United States
    - 1237.19.10094 Boehringer Ingelheim Investigational Site
  - Larchmont, New York, United States
    - 1237.19.10137 Boehringer Ingelheim Investigational Site
  - Syracuse, New York, United States
    - 1237.19.10143 Boehringer Ingelheim Investigational Site
- North Carolina
  - Burlington, North Carolina, United States
    - 1237.19.10035 Boehringer Ingelheim Investigational Site
  - Calabash, North Carolina, United States
    - 1237.19.10014 Boehringer Ingelheim Investigational Site
  - Charlotte, North Carolina, United States
    - 1237.19.10098 Boehringer Ingelheim Investigational Site
  - Charlotte, North Carolina, United States
    - 1237.19.10131 Boehringer Ingelheim Investigational Site
  - Elizabeth City, North Carolina, United States
    - 1237.19.10049 Boehringer Ingelheim Investigational Site
  - Gastonia, North Carolina, United States
    - 1237.19.10154 Boehringer Ingelheim Investigational Site
  - Hickory, North Carolina, United States
    - 1237.19.10104 Boehringer Ingelheim Investigational Site
  - Huntersville, North Carolina, United States
    - 1237.19.10087 Boehringer Ingelheim Investigational Site
  - Shelby, North Carolina, United States
    - 1237.19.10053 Boehringer Ingelheim Investigational Site
  - Wilmington, North Carolina, United States
    - 1237.19.10062 Boehringer Ingelheim Investigational Site
- Ohio
  - Cincinnati, Ohio, United States
    - 1237.19.10008 Boehringer Ingelheim Investigational Site
  - Cincinnati, Ohio, United States
    - 1237.19.10042 Boehringer Ingelheim Investigational Site
  - Columbus, Ohio, United States
    - 1237.19.10127 Boehringer Ingelheim Investigational Site
  - Dayton, Ohio, United States
    - 1237.19.10121 Boehringer Ingelheim Investigational Site
  - Dayton, Ohio, United States
    - 1237.19.10148 Boehringer Ingelheim Investigational Site
  - Delaware, Ohio, United States
    - 1237.19.10005 Boehringer Ingelheim Investigational Site
  - Kettering, Ohio, United States
    - 1237.19.10147 Boehringer Ingelheim Investigational Site
  - Toledo, Ohio, United States
    - 1237.19.10055 Boehringer Ingelheim Investigational Site
- Oklahoma
  - Tulsa, Oklahoma, United States
    - 1237.19.10146 Boehringer Ingelheim Investigational Site
- Oregon
  - Medford, Oregon, United States
    - 1237.19.10021 Boehringer Ingelheim Investigational Site
- Pennsylvania
  - Erie, Pennsylvania, United States
    - 1237.19.10129 Boehringer Ingelheim Investigational Site
  - Oaks, Pennsylvania, United States
    - 1237.19.10140 Boehringer Ingelheim Investigational Site
  - Philadelphia, Pennsylvania, United States
    - 1237.19.10003 Boehringer Ingelheim Investigational Site
  - Philadelphia, Pennsylvania, United States
    - 1237.19.10019 Boehringer Ingelheim Investigational Site
  - Pittsburgh, Pennsylvania, United States
    - 1237.19.10006 Boehringer Ingelheim Investigational Site
  - Pittsburgh, Pennsylvania, United States
    - 1237.19.10136 Boehringer Ingelheim Investigational Site
  - Pittsburgh, Pennsylvania, United States
    - 1237.19.10151 Boehringer Ingelheim Investigational Site
- Rhode Island
  - East Providence, Rhode Island, United States
    - 1237.19.10041 Boehringer Ingelheim Investigational Site
  - Johnston, Rhode Island, United States
    - 1237.19.10126 Boehringer Ingelheim Investigational Site
- South Carolina
  - Charleston, South Carolina, United States
    - 1237.19.10054 Boehringer Ingelheim Investigational Site
  - Columbia, South Carolina, United States
    - 1237.19.10086 Boehringer Ingelheim Investigational Site
  - Easley, South Carolina, United States
    - 1237.19.10058 Boehringer Ingelheim Investigational Site
  - Gaffney, South Carolina, United States
    - 1237.19.10023 Boehringer Ingelheim Investigational Site
  - Gaffney, South Carolina, United States
    - 1237.19.10030 Boehringer Ingelheim Investigational Site
  - Greenville, South Carolina, United States
    - 1237.19.10024 Boehringer Ingelheim Investigational Site
  - Greenville, South Carolina, United States
    - 1237.19.10128 Boehringer Ingelheim Investigational Site
  - Indian Land, South Carolina, United States
    - 1237.19.10099 Boehringer Ingelheim Investigational Site
  - Mount Pleasant, South Carolina, United States
    - 1237.19.10144 Boehringer Ingelheim Investigational Site
  - Myrtle Beach, South Carolina, United States
    - 1237.19.10071 Boehringer Ingelheim Investigational Site
  - Rock Hill, South Carolina, United States
    - 1237.19.10025 Boehringer Ingelheim Investigational Site
  - Spartanburg, South Carolina, United States
    - 1237.19.10033 Boehringer Ingelheim Investigational Site
  - Spartanburg, South Carolina, United States
    - 1237.19.10036 Boehringer Ingelheim Investigational Site
  - Union, South Carolina, United States
    - 1237.19.10010 Boehringer Ingelheim Investigational Site
- South Dakota
  - Rapid City, South Dakota, United States
    - 1237.19.10007 Boehringer Ingelheim Investigational Site
- Texas
  - Boerne, Texas, United States
    - 1237.19.10070 Boehringer Ingelheim Investigational Site
  - Corsicana, Texas, United States
    - 1237.19.10107 Boehringer Ingelheim Investigational Site
  - Fort Worth, Texas, United States
    - 1237.19.10153 Boehringer Ingelheim Investigational Site
  - Houston, Texas, United States
    - 1237.19.10047 Boehringer Ingelheim Investigational Site
  - Killeen, Texas, United States
    - 1237.19.10111 Boehringer Ingelheim Investigational Site
  - Kingwood, Texas, United States
    - 1237.19.10059 Boehringer Ingelheim Investigational Site
  - McKinney, Texas, United States
    - 1237.19.10061 Boehringer Ingelheim Investigational Site
  - San Antonio, Texas, United States
    - 1237.19.10050 Boehringer Ingelheim Investigational Site
- Virginia
  - Abingdon, Virginia, United States
    - 1237.19.10091 Boehringer Ingelheim Investigational Site
  - Lynchburg, Virginia, United States
    - 1237.19.10076 Boehringer Ingelheim Investigational Site
  - Richmond, Virginia, United States
    - 1237.19.10040 Boehringer Ingelheim Investigational Site
  - Richmond, Virginia, United States
    - 1237.19.10089 Boehringer Ingelheim Investigational Site
- Washington
  - Everett, Washington, United States
    - 1237.19.10123 Boehringer Ingelheim Investigational Site
  - Spokane, Washington, United States
    - 1237.19.10120 Boehringer Ingelheim Investigational Site
  - Tacoma, Washington, United States
    - 1237.19.10092 Boehringer Ingelheim Investigational Site
- West Virginia
  - Morgantown, West Virginia, United States
    - 1237.19.10001 Boehringer Ingelheim Investigational Site
- Wisconsin
  - West Allis, Wisconsin, United States
    - 1237.19.10016 Boehringer Ingelheim Investigational Site
Vietnam
- - Ha Noi, Vietnam
    - 1237.19.84003 Boehringer Ingelheim Investigational Site
  - Ho Chi Minh, Vietnam
    - 1237.19.84001 Boehringer Ingelheim Investigational Site
  - Ho Chi Minh, Vietnam
    - 1237.19.84002 Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Description

Inclusion criteria:

Male or female patients, 40 years of age or older.
Diagnosis of COPD with a documented post-bronchodilator Forced expiratory volume in one second (FEV1)< 60% of predicted normal and a post-bronchodilator FEV1/ forced vital capacity (FVC) <70% at Visit 1
Documented history of at least one moderate to severe COPD exacerbation in the previous 12 months requiring treatment with systemic corticosteroids and/or antibiotics and/or related hospitalization.
Symptomatically stable as defined by: no evidence of COPD exacerbation requiring use of either antibiotics and/or steroids 4 weeks prior to visit 1 and no evidence of change in their usual COPD medication 4 weeks prior to visit 1.
Current or ex-smokers with a smoking history of more than 10 pack years.

Exclusion criteria:

Significant disease other than COPD.
Clinically relevant abnormal baseline haematology, blood chemistry or creatinine > x2 ULN will be excluded regardless of clinical condition. ( A repeat laboratory evaluation can be conducted if deemed necessary by the investigator.)
Current documented diagnosis of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma
A diagnosis of thyrotoxicosis
A history of myocardial infarction within 6 months of screening visit.
Life-threatening cardiac arrhythmia.
Known active tuberculosis.
Any malignancy unless free of disease for at least 5 years (patients with treated basal cell carcinoma or squamous cell skin cancers are allowed).
A history of cystic fibrosis.
Clinically relevant bronchiectasis.
Patients with severe emphysema requiring endobronchial interventions within 6 months prior to screening
A history of significant alcohol or drug abuse in the opinion of the investigator.
Patients who have undergone thoracotomy with pulmonary resection
Patients being treated with oral or patch ß-adrenergics.
Patients being treated with oral corticosteroid medication at unstable doses
Patients being treated with antibiotics for any reasons within 4 weeks of screening visit
Patients being treated with PDE4 inhibitors within 3 months of screening visit
Patients who have taken an investigational drug within one month or six half-lives
Pregnant or nursing women.
Women of childbearing potential not using a highly effective method of birth control.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Double

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: tiotropium + olodaterol high dose Once daily 2 puffs solution for inhalation Respimat	Drug: tiotropium Drug: tiotropium fixed dose combination Drug: olodaterol fixed dose combination
Active Comparator: tiotropium Once daily 2 puffs solution for inhalation Respimat	Drug: tiotropium Drug: tiotropium fixed dose combination

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period. Time Frame: From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days	Annualised rate of moderate to severe COPD exacerbations during the actual treatment period was calculated per treatment per patient-year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. Least Squares Means are actually exponentiated.	From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients With at Least One Moderate to Severe COPD Exacerbation During the Actual Treatment Period. Time Frame: From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days	Key secondary endpoint: Number of patients with at least one moderate to severe COPD exacerbation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation is presented.	From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days
Annualised Rate of Exacerbations Leading to Hospitalisation During the Actual Treatment Period. Time Frame: From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days	Annualised rate of exacerbations leading to hospitalisation during the actual treatment period was calculated per treatment per patient-year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication.	From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days
Number of Patients With at Least One COPD Exacerbation Leading to Hospitalisation During the Actual Treatment Period. Time Frame: From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days	Number of patients with at least one COPD exacerbation leading to hospitalisation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation leading to hospitalisation is presented.	From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days
Number of Patients With All-cause Mortality Occurring During the Actual Treatment Period. Time Frame: From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days	Number of patients with all-cause mortality occurring during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with all-cause mortality is presented.	From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Related Info

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 13, 2015

Primary Completion (Actual)

March 8, 2017

Study Completion (Actual)

March 29, 2017

Study Registration Dates

First Submitted

November 19, 2014

First Submitted That Met QC Criteria

November 19, 2014

First Posted (Estimate)

November 20, 2014

Study Record Updates

Last Update Posted (Actual)

June 4, 2018

Last Update Submitted That Met QC Criteria

May 31, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

1237.19
2014-002275-28 (EudraCT Number: EudraCT)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Disease, Chronic Obstructive

Spire, Inc.
ResMed

Completed

An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD Subjects

Severe Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary Disease

United States
Karaganda Medical University

Completed

Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD (COPD)

Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease Severe

Kazakhstan
Randall Debattista
University of Malta, Faculty of Health Sciences

Not yet recruiting

Effect of NMES on Quadriceps Muscle Strength and Endurance in Patients With COPD (NMES)

Chronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
University of Leicester
University Hospitals, Leicester; University of Strathclyde

Recruiting

Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD (MuSiC)

Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease

United Kingdom
National Taipei University of Nursing and Health...

Terminated

Bubble PEP Training Among Patient With Chronic Obstructive Pulmonary Disease in Pulmonary Function Effects

Chronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With Exacerbation

Taiwan
Cukurova University

Completed

Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation

Anesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease Mild

Turkey
Mylan Inc.
Theravance Biopharma

Completed

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
University Hospital, Ghent
GlaxoSmithKline; University Ghent

Completed

Pharmaceutical Care for Chronic Obstructive Pulmonary Disease (COPD) Study. (PHARMACOP)

Chronic Obstructive Pulmonary Disease (COPD)

Belgium
Optimum Patient Care
Respiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company... and other collaborators

Unknown

Advancing the Patient Experience in Chronic Obstructive Pulmonary Disease (APEX COPD) (APEX COPD)

Chronic Obstructive Pulmonary Disease (13645005)

United States
Poitiers University Hospital

Completed

Interest of Branched Chain Amino Acids Associated With a Respiratory Rehabilitation Program in Patients Broncho Chronic Obstructive Pulmonary Disease (REHABAAR)

Broncho Chronic Obstructive Pulmonary Disease

France

Clinical Trials on tiotropium

Boehringer Ingelheim

Completed

Tiotropium Respimat Pharmacokinetic Study in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Denmark, Finland, Germany, Netherlands
Boehringer Ingelheim

Completed

Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

Pulmonary Disease, Chronic Obstructive

Austria, Germany, Canada, United States, Poland, Belgium, Portugal, United Kingdom, Australia, Denmark, New Zealand
Boehringer Ingelheim

Completed

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
Pfizer

Completed

Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.

Asthma

Austria, Germany, Ukraine
Boehringer Ingelheim

Completed

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Austria, Canada, Germany, Netherlands, Russian Federation, Sweden
Boehringer Ingelheim

Completed

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Canada, Chile, Germany, Italy, New Zealand
Boehringer Ingelheim

Completed

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Verona Pharma plc

Completed

The Effects of RPL554 in Addition to Tiotropium in COPD Patients

Chronic Obstructive Pulmonary Disease Moderate
Imperial College London
Boehringer Ingelheim

Completed

Airway Effects of Tiotropium in Patients With COPD

COPD | LUNG DISEASES, OBSTRUCTIVE

United Kingdom

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Publications and helpful links

General Publications

Helpful Links

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Clinical Trials on Pulmonary Disease, Chronic Obstructive

Clinical Trials on tiotropium

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations